The Global HIV Diagnostics Market is expected to reach USD 3422.08 million by 2021 owing to increasing prevalence of HIV/AIDS infection worldwide
Hyderabad, India -- (SBWIRE) -- 01/15/2018 -- The Global HIV Diagnostics Market was worth USD 2173.80 million in 2016 and estimated to be growing at a CAGR of 9.5%, to reach USD 3422.08 million by 2021.
HIV is the virus, which attacks the T-cells (CD-4 cells) in the immune system. AIDS is the syndrome, which appears in the advanced stage of HIV infection. HIV is found throughout all the tissues of the body but is transmitted via the body fluids of an infected person (semen, vaginal fluids, blood, and breast milk).AIDS (acquired immunodeficiency syndrome) is a syndrome caused by a virus called HIV (human immunodeficiency virus). The disease alters the immune system, making people much more vulnerable to infections and diseases. This susceptibility worsens as the syndrome progresses.
Sexual transmission, perinatal transmission; a mother can pass the infection on to her child during childbirth, pregnancy, and also through breastfeeding. Blood transmission; the risk of transmitting HIV through blood transfusion is nowadays extremely low in developed countries, thanks to meticulous screening and precautions. However, among injection or IV drug users, sharing and reusing syringes contaminated with HIV-infected blood is extremely hazardous.
The market for HIV diagnosis is showing progressive growth due to the increasing prevalence of HIV/AIDS infection worldwide, technological improvement of disease diagnostic tests, increase in awareness about HIV/AIDS increasing number of blood donations and blood transfusions. Another main reason for the rise in the number of HIV infection is the changing lifestyle, drugs addiction leading to injecting the drug, unprotected sex and lack of awareness in some regions. A key factor driving the market for HIV diagnosis is government efforts along with NGOs initiated against HIV/AIDS to lower the disease incidence and extend life expectancy through prolonged R&D efforts. The government initiative is an unstoppable factor in this case.
The financial resource-constrained settings in a huge share of the disease affected regions, it is as yet not feasible to perform the current, complex screening, staging and monitoring tests. This is either because of the absence of adequate testing labs or an absence of prepared clinical technicians capable of performing the tests. These limitations of laboratory-based testing are a catalyst for the improvement of convenient and simple to execute point of care, rapid tests.
The Global HIV Diagnostics Market is segmented on the basis of Product, Type, End-User and geography. Based on product, market is segmented into Consumables (Assays and Kits & Reagents, Other consumables), Instruments, Software & Services]. Based on Type, market is segmented into Antibody Tests, HIV-2 & Group O Diagnostic Tests, Viral Identification Tests, CD4 Testing, Viral load testing, Early Infant Diagnostics. Further on the basis of Antibody tests market is segmented into (HIV-1 Screening tests- Elisa/EIA, Rapid Tests, Home Access Dried blood spots), (HIV-1 Antibody Confirmatory Tests- Western Blot Test, Indirect immunofluorescence Assays(IFA), Line immunoassays(Cnf), Radio immunoprecipitation Assays(RIPA)). Based on HIV-2 & Group O Diagnostic Tests market is further dived into Blood Antibody Tests, DBS Tests, Line ImmunoAssay (HIV-2) and based on Viral Identification Tests, market is divided into p24 Antigen Test, Qualitative PCR Tests, Viral Culture. On the basis of geography, the global market is analysed under various regions namely North America, Europe, Asia-Pacific and Rest of the World. HIV Diagnostics Market was dominated by North America, with the overall market share of over 38% globally. North America was followed by Asia pacific. Asia Pacific is predicted to grow at a rapid pace in the coming few years, because of its high unmet demand in India and China.
Major players in the market are Abbott Healthcare, Alere Inc., Brsitol-Myers Squibb, Abbvie Inc., Gilead Sciences, Janssen Therapeutics, Merck & Co. Inc, BD Biosciences, VIIV Healthcare, Beckman Coulter, Partec, Sysmex, Apogee Flow Systems, Zyomyx Inc., Mylan inc., PointCare Technologies Inc., Roche Diagnostics, Qiagen, Siemens Healthcare, and bioMerieux dominated HIV diagnostics market share.
About Market Data Forecast
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, they cater to the needs of both individual and corporate clients. From all-encompassing umbrella markets to extremely specific niche markets covering all the major regions across the globe as part of the research scope, their research services offer one of a kind specialties with competitive pricing options.
For more information, kindly visit, http://www.marketdataforecast.com.